<DOC>
	<DOCNO>NCT00045162</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether cisplatin combine irinotecan effective cisplatin combine etoposide treat extensive-stage small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness cisplatin combine either irinotecan etoposide treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>S0124 : Cisplatin Combined With Irinotecan Etoposide For Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival patient extensive stage small cell lung cancer treat cisplatin irinotecan v cisplatin etoposide . - Compare objective response rate progression-free survival patient treat regimen . - Compare toxic effect regimens patient . - Determine association UGT1A1 polymorphisms irinotecan-associated toxic effect patient . - Determine association ERCC-1 XRCC-1 polymorphism non-response patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord number metastatic site ( single v multiple ) , lactic dehydrogenase ( great upper limit normal ( ULN ) vs great ULN ) , weight loss past 6 month ( 5 % less vs 5 % ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive irinotecan IV 90 minute day 1 , 8 , 15 cisplatin IV 30-60 minute day 1 . Courses repeat every 4 week . - Arm II : Patients receive etoposide IV 30-60 minute day 1-3 cisplatin IV 30-60 minute day 1 . Courses repeat every 3 week . Treatment arm continue 4 course absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 620 patient ( 310 per treatment arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm extensive stage small cell lung cancer ( SCLC ) Measurable evaluable disease CT scan , MRI , xray , physical exam , nuclear exam Brain metastases allow previously treat radiotherapy and/or surgery neurologically stable ( i.e. , progress symptom steroid anticonvulsant ) PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic WBC least 3,000/mm^3 Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN Renal Creatinine normal Creatinine clearance least 50 mL/min Other Not pregnant nursing Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix HIV negative No concurrent AIDSrelated illness PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy SCLC No filgrastim ( GCSF ) within 24 hour chemotherapy Chemotherapy No prior systemic chemotherapy SCLC Endocrine therapy See Disease Characteristics Radiotherapy See Disease Characteristics At least 21 day since prior brain radiotherapy recover No prior radiotherapy SCLC Surgery See Disease Characteristics At least 21 day since prior thoracic major surgery recover Other No concurrent enzyme induce antiepileptic drug ( phenytoin , phenobarbital , oxcarboxepine , carbamazepine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>